Net Selling Behind Korea Exchange’s ‘Investment Caution’ Designation for Baropharm Matches KB Fund’s Sales…Concerns Over Additional Share Sales in December by Kookmin Bank-Backed Fund
English translation of the original Korean report. Images and source documents may contain Korean text.

Two KB Financial Group-Affiliated Funds Sell 691,670 Shares on Listing Day…Stock Plunges 65.79% Below IPO Price
Funds with KB Investment and Kookmin Bank as Largest Investors Face December 11 Lock-Up Expiration on Remaining 691,671 Shares
Baropharm is facing growing pressure from potential additional share sales after its stock plunged 65.79% below its IPO price within eight trading days of its KOSDAQ listing.
This is because the remaining 691,671 shares held by two KB Financial Group-affiliated funds, which sold half of their holdings on the first day of trading, will become eligible for sale starting December 11.
A comparison of Financial Supervisory Service disclosures and Baropharm’s revised investment prospectus on the 20th showed that the KB Global Platform Fund, managed by KB Investment, a subsidiary of KB Financial Group, sold 433,836 shares on the exchange on the 11th, while the KB Digital Platform Fund sold 257,834 shares.
The two funds sold a combined 691,670 shares on the first day of trading, with total proceeds calculated at 9,284,184,436 won based on the disclosed transaction prices.
Following the sales, the KB Global Platform Fund, in which KB Investment has contributed a 50% stake, retained 433,837 shares, while the KB Digital Platform Fund, whose largest investor is KB Kookmin Bank with a 46.6% stake, retained 257,834 shares.
■ Korea Exchange Issues Investment Caution Designation…Net Selling Volume Matches KB Fund’s Share Sales
The Korea Exchange confirmed that 433,836 shares were net sold through a particular account on Baropharm’s first trading day and designated the company an investment caution stock on the following day, the 12th, due to high trading volume concentrated in a single account.
That figure exactly matches the number of shares sold by the KB Global Platform Fund, but although the exchange classified the account as an individual account, publicly available information does not establish whether the two transactions were conducted through the same account.
Two Company K-affiliated funds were also confirmed to have sold a combined 97,356 shares on the first day of trading, meaning the KB-affiliated funds were not the only existing investors to dispose of shares.
Baropharm closed at 5,610 won on the 20th, down 10,790 won from its IPO price of 16,400 won, representing a decline of 65.79% from the offering price.
On December 11, lock-up restrictions will expire on an additional 3,244,703 shares held by existing shareholders, including the remaining holdings of the KB-affiliated funds, increasing the cumulative proportion of shares eligible for trading to 57.45%. However, it has not been confirmed whether the KB funds will actually sell additional shares or to what extent their earlier sales contributed to the stock’s decline.
